Additionally, in the longitudinal analysis, participants with the greatest 3‐year increases in irisin had higher odds of obesity, abdominal obesity, sarcopenia, low ALST and sarcopenic obesity at follow‐up compared to those with the least increase or with decreased irisin. This evidence concerns the gene FNDC5 and Abdominal obesity.